CTMX - CytomX Therapeutics Inc Stock Price, Fair Value and News

4.43USD-0.07 (-1.56%)Delayed

Market Summary

USD4.43-0.07

Delayed

-1.56%

CTMX Stock Price

View Fullscreen

CTMX RSI Chart

CTMX Valuation

Market Cap

300.0M

Price/Earnings (Trailing)

-527.25

Price/Sales (Trailing)

2.96

EV/EBITDA

-10.78

Price/Free Cashflow

-5.27

CTMX Price/Sales (Trailing)

CTMX Profitability

EBT Margin

-29.76%

Return on Equity

1.2%

Return on Assets

-0.28%

Free Cashflow Yield

-18.96%

CTMX Fundamentals

CTMX Revenue

Revenue (TTM)

101.2M

Rev. Growth (Yr)

32.22%

Rev. Growth (Qtr)

0.85%

CTMX Earnings

Earnings (TTM)

-569.0K

Earnings Growth (Yr)

109.54%

Earnings Growth (Qtr)

-72.03%

Breaking Down CTMX Revenue

Last 7 days

179.9%

Last 30 days

107.0%

Last 90 days

200.7%

Trailing 12 Months

166.5%

How does CTMX drawdown profile look like?

CTMX Financial Health

Current Ratio

1.17

CTMX Investor Care

Shares Dilution (1Y)

2.26%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	67.6M	79.5M	94.7M	101.2M
2022	38.2M	42.2M	44.2M	53.2M
2021	29.7M	31.5M	33.3M	37.3M
2020	74.9M	72.9M	69.6M	68.4M
2019	74.8M	62.5M	60.7M	57.5M
2018	74.2M	86.7M	75.1M	59.5M
2017	24.5M	30.1M	50.8M	71.6M
2016	8.2M	9.2M	10.8M	15.0M
2015	6.2M	7.6M	7.6M	7.7M
2014	1.9M	3.0M	4.0M	5.1M
2013	0	0	0	888.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CytomX Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	mccarthy sean a.	acquired	172,874	1.5749	109,768	ceo
Mar 19, 2024	rowland lloyd a	sold	-10,986	2.0855	-5,268	general counsel
Mar 19, 2024	landau jeffrey b	sold	-13,685	2.0855	-6,562	chief business officer
Mar 19, 2024	ogden christopher	sold	-6,196	2.0855	-2,971	svp, finance and accounting
Mar 19, 2024	mccarthy sean a.	sold	-42,175	2.0855	-20,223	ceo
Mar 19, 2024	belvin marcia	sold	-26,684	2.0855	-12,795	svp, chief scientific officer
Jan 18, 2024	chu yu-waye	acquired	-	-	26,250	chief medical officer
Jan 18, 2024	rowland lloyd a	acquired	-	-	25,000	general counsel
Jan 18, 2024	mccarthy sean a.	acquired	-	-	90,000	ceo
Jan 18, 2024	belvin marcia	acquired	-	-	26,250	svp, chief scientific officer

Which funds bought or sold CTMX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	WHITTIER TRUST CO	unchanged	-	4,226	14,396	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	49.00	170	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Private Advisor Group, LLC	reduced	-5.47	37,383	150,810	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	unchanged	-	33,000	116,000	-%
Apr 25, 2024	WestHill Financial Advisors, Inc.	unchanged	-	10,762	37,239	0.01%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-9.31	113,923	527,519	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	13,000	13,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	unchanged	-	254,944	882,189	-%
Apr 22, 2024	Byrne Asset Management LLC	sold off	-100	-12,400	-	-%

Are Funds Buying or Selling CTMX?

Are funds buying CTMX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTMX

No. of Funds

Unveiling CytomX Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	5.4%	3,651,391	SC 13G/A
Feb 14, 2024	tang capital partners lp	9.8%	6,550,000	SC 13G/A
Feb 13, 2024	vanguard group inc	7.32%	4,902,943	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2023	tang capital partners lp	5.3%	3,510,445	SC 13G/A
Feb 09, 2023	vanguard group inc	6.94%	4,585,721	SC 13G/A
Jul 29, 2022	biotechnology value fund l p	5.4%	3,544,303	SC 13G/A
Jul 08, 2022	blackrock inc.	2.8%	1,826,591	SC 13G
Feb 14, 2022	rtw investments, lp	9.2%	6,029,700	SC 13G/A

Recent SEC filings of CytomX Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	DEFA14A	DEFA14A
Mar 28, 2024	4	Insider Trading
Mar 25, 2024	PRE 14A	PRE 14A
Mar 22, 2024	3	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading

Peers (Alternatives to CytomX Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

CytomX Therapeutics Inc News

Latest updates

CytomX Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.8%	26,607,000	26,384,000	24,724,000	23,499,000	20,123,000	11,147,000	12,853,000	9,040,000	11,132,000	9,189,000	8,795,000	8,197,000	7,078,000	7,466,000	6,988,000	46,895,000	8,279,000	10,712,000	9,013,000	29,485,000	11,471,000
Operating Expenses	17.0%	27,213,000	23,261,000	28,072,000	29,152,000	29,631,500	40,857,000	42,907,000	41,102,000	46,035,000	40,228,000	35,493,000	31,598,000	31,152,000	32,683,000	32,746,000	52,386,000	45,658,000	36,430,000	40,246,000	46,050,000	37,281,000
S&GA Expenses	14.9%	7,827,000	6,813,000	7,401,000	7,977,000	10,067,500	10,490,000	11,748,000	10,543,000	9,455,000	11,085,000	9,393,000	9,227,000	9,145,000	8,634,000	8,680,000	9,572,000	9,217,000	8,463,000	9,411,000	9,674,000	8,975,000
R&D Expenses	17.9%	19,386,000	16,448,000	20,671,000	21,175,000	19,564,000	30,367,000	31,159,000	30,559,000	36,580,000	29,143,000	26,100,000	22,371,000	22,007,000	24,049,000	24,066,000	42,814,000	36,441,000	27,967,000	30,835,000	36,376,000	28,306,000
EBITDA Margin	57.4%	-0.26	-0.61	-1.20	-1.41	-1.80	-2.75	-2.92	-3.16	-3.00	-3.04	-3.02	-3.15	-	-	-	-	-	-	-	-	-
Income Taxes	-62.1%	1,069,000	2,823,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,911,000	-421,000	-	-	-6,000	8,912,000
Earnings Before Taxes	-67.2%	1,906,000	5,815,000	-	-	-8,775,500	-29,064,000	-29,496,000	-31,981,000	-34,823,000	-30,982,000	-26,736,000	-23,328,000	-23,996,000	-25,032,000	-25,299,000	-4,404,000	-66,463,500	-23,699,000	-28,960,000	-14,130,000	-23,321,000
EBT Margin	54.2%	-0.30	-0.65	-1.25	-1.47	-1.87	-2.84	-3.02	-3.26	-3.11	-3.16	-3.14	-3.28	-	-	-	-	-	-	-	-	-
Net Income	-72.0%	837,000	2,992,000	-1,087,000	-3,311,000	-8,775,500	-29,064,000	-29,496,000	-31,981,000	-34,823,000	-30,982,000	-26,736,000	-23,328,000	-23,996,000	-25,032,000	-25,299,000	9,507,000	-35,455,000	-23,699,000	-28,960,000	-14,124,000	-32,233,000
Net Income Margin	94.8%	-0.01	-0.11	-0.53	-1.04	-1.87	-2.84	-3.02	-3.26	-3.11	-3.16	-3.14	-3.28	-	-	-	-	-	-	-	-	-
Free Cashflow	-21.8%	-22,229,000	-18,252,000	-25,695,000	9,301,000	-1,575,000	-34,255,000	-34,649,000	-42,049,000	-31,437,000	-29,968,000	-28,313,000	-30,922,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.8%	202	221	209	235	261	226	260	297	339	371	402	434	359	375	402	437	341	373	405	445	457
Current Assets	-9.1%	183	201	188	212	237	200	233	268	310	241	271	400	324	340	367	400	303	335	367	405	445
Cash Equivalents	-34.0%	17.00	26.00	58.00	56.00	194	95.00	129	163	206	236	256	330	192	177	291	143	188	165	149	190	248
Net PPE	-2.5%	4.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-8.5%	249	272	294	321	347	307	315	327	340	341	344	353	366	327	344	367	290	290	304	322	326
Current Liabilities	6.2%	156	147	141	151	153	124	95.00	87.00	78.00	68.00	60.00	65.00	68.00	102	99.00	106	86.00	76.00	79.00	96.00	98.00
Shareholder's Equity	-Infinity%	-47.45	-	-	-	-85.75	28.00	49.00	68.00	89.00	30.00	58.00	81.00	50.00	48.00	59.00	70.00	25.00	82.00	102	123	136
Retained Earnings	0.1%	-723	-724	-727	-726	-722	-714	-685	-655	-623	-588	-557	-531	-507	-435	-420	-405	-442	-381	-358	-329	-314
Additional Paid-In Capital	0.4%	676	673	642	640	637	634	632	627	623	619	616	612	500	484	480	474	468	464	459	452	446
Shares Outstanding	-16.6%	67.00	81.00	66.00	66.00	66.00	66.00	66.00	65.00	65.00	64.00	63.00	61.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	114	-	-	-	118	-	-	-	408	-	-	-	379	-	-	-	502	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.4%	-21,963	-18,243	-25,178	9,349	-1,393	-33,845	-34,237	-41,313	-31,192	-29,700	-28,199	-29,940	-17,427	-24,678	97,101	-49,737	-29,479	-23,319	-48,653	-39,029	-28,742
Share Based Compensation	108.2%	2,552	1,226	2,371	2,409	2,570	2,695	4,490	3,370	3,544	3,164	3,425	3,034	3,419	3,841	3,513	4,013	4,111	4,343	5,454	5,192	4,616
Cashflow From Investing	130.0%	12,866	-42,938	26,040	-146,642	99,818	-410	-412	-736	-245	9,734	-46,012	59,012	19,455	-90,067	49,453	2,441	52,857	38,510	6,940	-18,606	15,842
Cashflow From Financing	-99.2%	244	29,669	317	-	190	-	451	7.00	683	104	691	108,735	13,021	167	1,548	2,157	401	63.00	698	465	724

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CTMX Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Revenue	$ 101,214	$ 53,163
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 77,680	$ 111,649
General and administrative	30,018	42,849
Total operating expenses	107,698	154,498
Loss from operations	(6,484)	(101,335)
Interest income	9,837	1,678
Other income (expense), net	(30)	340
Income (Loss) before income taxes	3,323	(99,317)
Provision for income taxes	3,892	0
Net loss	(569)	(99,317)
Other comprehensive loss:
Unrealized gain on available-for-sale investments, net of tax	85	252
Total comprehensive loss	$ (484)	$ (99,065)
Net loss per share, Basic	$ (0.01)	$ (1.51)
Net loss per share, Diluted	$ (0.01)	$ (1.51)
Shares used to compute net loss per share, Basic	73,808,237	65,739,844
Shares used to compute net loss per share, Diluted	73,808,237	65,739,844

CTMX Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,171	$ 193,650
Short-term investments	157,338	0
Accounts receivable	3,432	35,986
Prepaid expenses and other current assets	4,995	7,466
Total current assets	182,936	237,102
Property and equipment, net	3,958	5,072
Intangible assets, net	729	875
Goodwill	949	949
Restricted cash	917	917
Operating lease right-of-use asset	12,220	15,949
Other assets	83	27
Total assets	201,792	260,891
Current liabilities:
Accounts payable	1,458	2,809
Accrued liabilities	17,599	24,450
Operating lease liabilities - short term	4,589	4,082
Deferred revenues, current portion	132,267	121,267
Total current liabilities	155,913	152,608
Deferred revenue, net of current portion	80,048	180,059
Operating lease liabilities - long term	9,385	13,975
Other long-term liabilities	3,893	0
Total liabilities	249,239	346,642
Commitments and contingencies (Note 10)
Stockholders' deficit
Common stock, $0.00001 par value; 150,000,000 shares authorized, and 67,310,838 and 66,228,046 shares issued and outstanding at December 31, 2023 and 2022, respectively	1	1
Additional paid-in capital	675,905	637,117
Accumulated other comprehensive income	95	10
Accumulated deficit	(723,448)	(722,879)
Total stockholders' deficit	(47,447)	(85,751)
Total liabilities and stockholders' deficit	201,792	260,891
Convertible Preferred Stock
Stockholders' deficit
Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding	$ 0	$ 0

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CEO	Dr. Sean A. McCarthy D.Phil., DPHIL
WEBSITE	cytomx.com
INDUSTRY	Biotechnology
EMPLOYEES	116

CytomX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for CytomX Therapeutics Inc? What does CTMX stand for in stocks?

CTMX is the stock ticker symbol of CytomX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytomX Therapeutics Inc (CTMX)?

As of Fri May 03 2024, market cap of CytomX Therapeutics Inc is 301.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTMX stock?

You can check CTMX's fair value in chart for subscribers.

What is the fair value of CTMX stock?

You can check CTMX's fair value in chart for subscribers. The fair value of CytomX Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CytomX Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTMX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CytomX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CTMX is over valued or under valued. Whether CytomX Therapeutics Inc is cheap or expensive depends on the assumptions which impact CytomX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTMX.

What is CytomX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, CTMX's PE ratio (Price to Earnings) is -529.63 and Price to Sales (PS) ratio is 2.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTMX PE ratio will change depending on the future growth rate expectations of investors.